1. J Thorac Oncol. 2019 Aug;14(8):e157-e159. doi: 10.1016/j.jtho.2019.04.020.
Epub  2019 May 7.

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in 
trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine 
Kinase Inhibitors.

Zhou Z(1), Zhao Y(1), Shen S(1), Gu L(1), Niu X(1), Xu Y(1), Zhang T(2), Xiang 
J(2), Mao X(2), Lu S(3).

Author information:
(1)Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong 
University, Shanghai, China.
(2)Burning Rock Biotech, Guangzhou, China.
(3)Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong 
University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn.

Comment in
    J Thorac Oncol. 2020 Nov;15(11):e181-e182. doi: 10.1016/j.jtho.2020.04.022.
    J Thorac Oncol. 2020 Nov;15(11):e182-e183. doi: 10.1016/j.jtho.2020.07.016.

DOI: 10.1016/j.jtho.2019.04.020
PMID: 31075545 [Indexed for MEDLINE]